Bank Julius Baer & Co
DFTX

Bank Julius Baer & Co’s Definium Therapeutics DFTX Stock Holding History

Bank Julius Baer & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-837
Closed -$17K – 717
2021
Q4 		$17K Buy
+837
New +$26.7K ﹤0.01% 754
2021
Q3 		– Sell
-345
Closed -$18K – 844
2021
Q2 		$18K Buy
+345
New +$18.1K ﹤0.01% 760

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Bank Julius Baer & Co's DFTX Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 837 shares — an estimated $17K sold.

Bank Julius Baer & Co first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $18K in Q2 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Bank Julius Baer & Co reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 837 Definium Therapeutics shares in Q1 2022, an estimated $17K.
  • Bank Julius Baer & Co first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
  • Bank Julius Baer & Co's Definium Therapeutics position peaked at $18K in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.